Here, we found that VASH2 is expressed at high levels in human pancreatic cancer cells and acts as a gemcitabine-resistance factor, and the expression of RRM2 could be upregulated by VASH2 in a JUN-dependent manner. This evidence concerns the gene JUN and pancreatic neoplasm.